Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Neurocrine Biosciences, Inc. - Common Stock (NQ:NBIX)

130.92 +0.99 (+0.76%)
Streaming Delayed Price Updated: 1:55 PM EDT, Mar 10, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 414,868
Open 130.42
Bid (Size) 130.78 (400)
Ask (Size) 131.10 (200)
Prev. Close 129.93
Today's Range 129.07 - 131.90
52wk Range 84.23 - 160.18
Shares Outstanding 100,100,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
The Potassium Channel Breakthrough: A Deep-Dive on Xenon Pharmaceuticals (XENE)
As of March 10, 2026, the biopharmaceutical sector is witnessing a historic realignment in the neurology space, spearheaded by the Canadian-born clinical powerhouse Xenon Pharmaceuticals Inc. (Nasdaq:... 
Via Finterra
Topics Economy Initial Public Offering Intellectual Property
Neurocrine Biosciences Inc (NASDAQ:NBIX) Shows Strong Fundamentals and a Bullish Chart Pattern ↗
Via Chartmill

Performance

YTD
-6.9%
-6.9%
1 Month
-6.2%
-6.2%
3 Month
-15.5%
-15.5%
6 Month
-9.0%
-9.0%
1 Year
+18.1%
+18.1%

More News

Read More
News headline image
Xenon Stock at $42: What to Know of a $75 Million Trim Ahead of March Phase 3 Data ↗
Via The Motley Fool
Topics Regulatory Compliance
Neurocrine Biosciences Inc (NASDAQ:NBIX) Fits the GARP Strategy with Strong Growth and Reasonable Valuation ↗
Via Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX) Screens as a Compelling Value Investment ↗
Via Chartmill
Neurocrine Biosciences Inc (NASDAQ:NBIX) Reports Q4 2025 Earnings Miss Amid Strong Annual Sales Growth ↗
Via Chartmill
Topics Earnings
Neurocrine Biosciences Inc (NASDAQ:NBIX) Presents a Compelling Mix of Strong Fundamentals and Bullish Technical Setup ↗
Via Chartmill
News headline image
Inside a $58 Million Bet on Kodiak Amid $184 Million Offering and Phase 3 Readouts Ahead ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
This Fund Just Disclosed a New $55 Million Bet on Centessa Amid 53% Stock Rally and CEO Transition ↗
Via The Motley Fool
News headline image
CG Oncology Soars 102% in a Year, but One Investor Just Disclosed a $58.5 Million Sale ↗
Via The Motley Fool
Topics Regulatory Compliance
Neurocrine Biosciences Inc (NASDAQ:NBIX) Emerges as a Prime Affordable Growth Stock ↗
Via Chartmill
Neurocrine Biosciences Inc. (NASDAQ:NBIX) Presents a Compelling Value Investment Case ↗
Via Chartmill
CRNX Stock Gains, NBIX Shares Drop On Positive Results From Genetics Disorder Trial ↗
Via Stocktwits
News headline image
BrightSpring Stock Up 86% as Braidwell Takes $45 Million Stake in Healthcare Services Provider ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Neurocrine (NBIX) Q4 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Neurocrine Biosciences Inc (NASDAQ:NBIX) Offers a Prime Example of Growth at a Reasonable Price ↗
Via Chartmill
News headline image
Neurocrine Biosciences Inc (NASDAQ:NBIX) Combines Strong Fundamentals with Bullish Technical Setup ↗
Via Chartmill
News headline image
Up 44% Since IPO: Why a Major Fund Just Made a $45 Million Bet on This Digital Health Stock ↗
Via The Motley Fool
Topics Initial Public Offering Regulatory Compliance
News headline image
Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound? ↗
Via The Motley Fool
News headline image
Soleno Turns First Profit on $66 Million in Revenue — Is This Why One Investor Just Made an $87 Million Bet? ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Neurocrine (NBIX) Q3 2025 Earnings Call Transcript ↗
Via The Motley Fool
Topics Earnings
News headline image
Medicare Slashes Ozempic's Price Tag 71%; Why Novo Nordisk Rallied ↗
Via Investor's Business Daily
Topics Economy Government
News headline image
This Fund Sold $30 Million in PTC Therapeutics Shares Amid a 93% Rally: Here’s Why ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Why This Fund Trimmed a $161 Million Travere Position After a 100% Rally ↗
Via The Motley Fool
News headline image
High Growth Momentum Stock NEUROCRINE BIOSCIENCES INC (NASDAQ:NBIX) Shows Strong Earnings Acceleration ↗
Via Chartmill

Frequently Asked Questions

Is Neurocrine Biosciences, Inc. - Common Stock publicly traded?
Yes, Neurocrine Biosciences, Inc. - Common Stock is publicly traded.
What exchange does Neurocrine Biosciences, Inc. - Common Stock trade on?
Neurocrine Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Neurocrine Biosciences, Inc. - Common Stock?
The ticker symbol for Neurocrine Biosciences, Inc. - Common Stock is NBIX on the Nasdaq Stock Market
What is the current price of Neurocrine Biosciences, Inc. - Common Stock?
The current price of Neurocrine Biosciences, Inc. - Common Stock is 130.92
When was Neurocrine Biosciences, Inc. - Common Stock last traded?
The last trade of Neurocrine Biosciences, Inc. - Common Stock was at 03/10/26 01:55 PM ET
What is the market capitalization of Neurocrine Biosciences, Inc. - Common Stock?
The market capitalization of Neurocrine Biosciences, Inc. - Common Stock is 13.11B
How many shares of Neurocrine Biosciences, Inc. - Common Stock are outstanding?
Neurocrine Biosciences, Inc. - Common Stock has 13B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.